Oxford BioMedica plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Oxford BioMedica plc
In an interview with Medtech Insight, Sharrolyn Josse, worldwide president of VELYS Digital Surgery and Capital at Johnson & Johnson’s DePuy Synthes unit, outlines strategies that are driving the present and future VELYS robotic-assisted solution and its connected technologies.
In the latest sign that some multinationals are scaling down operations in the world's second-largest pharma market, Mundipharma is reported to be exploring the sale of its business in China, with a large group of bidders including state-owned Sinopharm and local private equity firm Boyu Capital in the running.
Created to take on Nasdaq in the US, the Shanghai Stock Exchange’s STAR Market is celebrating its two-year anniversary with star performers such as CanSino. But its viability as an alternative will be tested by BeiGene, which is set to start trading in Shanghai following dual listings in New York and Hong Kong, with the latter continuing to attract other biopharma IPOs.
To bolster its life sciences and diagnostics portfolios, Novo Holdings has made another major investment to acquire BBI Group.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Oxxon Therapeutics Limited